Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors : Preventing deleterious ‘de-hinging’ to improve tolerability.
DeuterOncology NV was founded in September 2020 by Dr Timothy Perera and is based in Liege in Belgium
Terms and Conditions | Privacy Policy
©2024 by DeuterOncology
Designed by RevWolf